ABSTRACT
Objectives Individuals with Down syndrome (DS) display high risk of celiac disease (CD), but the mechanisms underlying this increased susceptibility await elucidation. Here, we examined the prevalence of HLA genotypes associated with CD risk in the general population and tested a previously developed genetic risk score (GRS) for CD in people with DS.
Methods HLA genotypes were obtained for 204 individuals with DS in the Human Trisome Project cohort study, of whom 9% had CD. We compared HLA genotype frequencies in those with and without CD against frequencies observed in the general population. CD permissive HLA haplotypes explored were DQ2.5, DQ2.2, DQ8.1, and DQ7.5. We also analyzed 38 non-HLA-DQ alleles used to generate the CD GRS.
Results Frequencies of risk genotypes were different for CD in DS versus CD in the general population. For example, we observed lower frequency of DQ2.5/DQ2.5 and higher prevalence of DQ7.5/X and X/X in CD in DS. Although GRS values were significantly increased in those with CD and DS, their predictive power was decreased relative to the general population. Transcriptome analysis revealed dysregulated expression of many genes composing the GRS in DS. Proteomics analysis showed that GRS values correlate with elevation of specific immune factors in DS.
Conclusions The genetic risk profile of CD in DS is different relative to the general population, which is likely due to dysregulation of immune pathways in DS. Larger studies are needed to elucidate pathogenic mechanisms and to develop a validated GRS for CD in DS.
What is Known
Celiac disease is more common in individuals with Down syndrome, but the impact of HLA risk genotypes in this population is unclear.
A celiac disease genetic risk score incorporating HLA-DQ and non-HLA SNPs has been developed with good predictive accuracy in the general population.
What is New
Individuals with DS may still develop CD even without the traditional HLA-DQ risk factors.
A modified CD genetic risk score may be applied to individuals with DS with good accuracy and specificity.
The immune dysregulation characteristic of DS involves dysregulated expression of many genes involved in CD etiology.
Competing Interest Statement
R.J.S. serves on the advisory committee for Mirum Pharma and Abireo Pharma and is a consultant for Astellas.
Funding Statement
This study was funded by the NIH Office of the Director via the NIH INCLUDE Project through NIAID grant R01AI150305, and NCATS grants 5UL1TR002535 and KL2-TR002534. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding was provided by the Linda Crnic Institute for Down Syndrome, the GLOBAL Down Syndrome Foundation, the Anna and John J. Sie Foundation, the GI & Liver Innate Immune Program, the Human Immunology and Immunotherapy Initiative, and the University of Colorado School of Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Colorado Multiple Institutional Review Board (COMIRB) gave ethical approval of this work under protocol numbers COMIRB# 15-2170 and COMIRB# 20-1977. See also clinicaltrials.gov entry NCT02864108.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- (CD)
- Celiac Disease
- (D21)
- Disomy 21
- (DS)
- Down Syndrome
- (GRS)
- Genetic Risk Score
- (HLA)
- Human Leukocyte Antigen
- (IFN)
- Interferon
- (T21)
- Trisomy 21
